EXOSC9

Across TCGA pan-cancer cohorts, EXOSC9 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EXOSC9 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EXOSC9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXOSC9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, COAD, and LSCC are the cancer types where EXOSC9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.599	0.889	.001	15	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.631	.009	6	view →
HNSC	DFS	Median	All	0.705	0.846	.022	5	view →
PDAC	DFS	Quartile	All	0.589	0.334	.018	4	view →
GBM	OS	Median	All	0.495	0.297	.020	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.841	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EXOSC9–LUAD (OS)

Open the LUAD breakdown →